Bevacizumab-treated eyes had better visual acuity at 3 months.
Intravitreal bevacizumab for choroidal neovascularization secondary to presumed ocular histoplasmosis syndrome.
Rita Ehrlich … Alon Harris
Retina (Philadelphia, Pa.) · Nov 2009 · Q1 in Ophthalmology
Purpose
The purpose of this study was to assess the efficacy of intravitreal bevacizumab for choroidal neovascularization resulting from presumed ocular histoplasmosis syndrome.
Methods
This is a chart review of retrospective consecutive case series in which intravitreal bevacizumab (1.25 mg) was injected into 24 eyes with choroidal neovascularization resulting from presumed ocular histoplasmosis syndrome.
n = 24 eyes
20/55
Results
20/55
average ability to see clearly was better after 3 months
n = 24 eyes
More results
The average number of bevacizumab injections was 6.8 injections/year.
“
Conclusion
Intravitreal injection of bevacizumab seems to be an effective treatment for choroidal neovascularization resulting from presumed ocular histoplasmosis syndrome.
